2 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
CytOSorb TreatMent Of Critically Ill PatientS RegistryAcute-On-Chronic Liver Failure, Chemically-Induced Disorders, Digestive System Diseases, Disease Attributes, Drug Misuse, Drug Overdose, Hemic and Lymphatic Diseases, Hepatic Insufficiency, Infarction, Infections, Inflammation, Lymphohistiocytosis, Hemophagocytic, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Postoperative Vasoplegic Syndrome, Prescription Drug Misuse, Respiration Disorders, Rhabdomyolysis, Sepsis, Shock, Shock, Cardiogenic, Systemic Inflammatory Response Syndrome, Vasoplegia, acute liver failure, adult acute respiratory distress syndrome, burn, cardiovascular disorder, cytokine release syndrome, heart disorder, histiocytosis, infectious disease, injury, ischemic disease, liver disorder, liver failure, lung disorder, lymphatic system disorder, muscle tissue disorder, musculoskeletal system disorder, myocardial infarction, myocardial ischemia, non-Langerhans cell histiocytosis, pancreas disorder, pancreatitis, psychiatric disorder, respiratory system disorder, substance-related disorder, toxic shock syndrome, vascular disorderRecruitingNot stated2025-09-11NCT05146336
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular CarcinomaDigestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasmRecruitingPhase 32025-01-07NCT04803994